Where is Merck & Co. (MRK) Headed According to Analysts?

Merck & Co., Inc. (NYSE:MRK) is one of the best drug stocks to buy right now. On September 10, Leerink Partners analyst Daina Graybosch maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK), giving the stock a Buy rating.

The analyst gave the optimistic rating due to Merck & Co., Inc.’s (NYSE:MRK) strategic position in the competitive landscape of antibody-drug conjugates (ADCs) to treat extensive-stage small cell lung cancer (ES-SCLC).

J.P. Morgan analyst Chris Schott also maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK) on the same day, giving the stock a Buy rating with a price target of $120.00.

Merck & Co., Inc. (NYSE:MRK) has an analyst consensus of Moderate Buy, and its median price target of $82.81 implies an upside of 20.76% from current levels.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.